FDA Panel Rejects Sonablate 450 HIFU Device For Prostate Cancer
This article was originally published in The Gray Sheet
Executive Summary
The advisors voted almost unanimously that SonaCare Medical’s HIFU device did not have good enough data to support a positive risk-benefit profile, but they suggested the company could improve their trial design and try again.
You may also be interested in...
HIFU Face-Off: US Competition Begins For Prostate High-Intensity Focused Ultrasound
With the 510(k) clearance of EDAP TMS' Ablatherm HIFU and the first US procedure performed with SonaCare Medical's recently cleared Sonablate system, a European rivalry in high-intensity focused ultrasound machines for prostate cancer has moved to the US. And EDAP's CEO argues it was positive for long-term adoption that his firm's system ultimately gained 510(k) clearance as a surgical tool rather than the originally sought PMA approval for a prostate cancer indication.
De Novo Cleared For Sonablate Device After Panel Rejects PMA
The ultrasound unit for the ablation of prostate tissue was cleared via the de novo process. Last year, an FDA advisory panel recommended against approving a PMA on the device due to what the experts said were insufficient clinical trial results.
FDA Recommends Narrowed Indication For EDAP’s Ablatherm-HIFU
The agency sent EDAP TMS a not-approvable letter for its high intensity focused ultrasound device, asking the company to narrow its sought prostate cancer indication and provide additional safety and efficacy data by next spring.